Masataka Oitate

Masataka Oitate

Auto-generated profile, based on publicly available information

Masataka Oitate

Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
MOMasataka Oitate
Masataka Oitate
NMNoriko Masubuchi
Noriko Masubuchi
TITakashi Ito
Takashi Ito
YYYoshiyuki Yabe
Yoshiyuki Yabe
TKTsuyoshi Karibe
Tsuyoshi Karibe
TITakashi Izumi
Takashi Izumi
Interspecies allometric scaling is a useful tool for calculating human pharmacokinetic (PK) parameters from data in animals. In this study, in order to determine the scaling exponent in a simple allometric equation that can predict human clearance (CL) and distribution volume at steady state (Vss) of monoclonal antibodies (mAbs) from monkey data alone, PK data of 24 mAbs were collected and analyzed according to the types of targeted antigens (soluble or membrane-bound antigens). Based on the observed PK data in humans (at clinical doses) and monkeys (at >1 mg/kg), where the PK is expected to be linear, the mean scaling exponents in the allometric equation for CL and Vss, respectively, against body weight were calculated to be 0.79 and 1.12 [95% confidence intervals (CIs): 0.69-0.89 and 0.96-1.28] for soluble antigens, and 0.96 and 1.00 (95% CIs: 0.83-1.09 and 0.87-1.13) for membrane-bound antigens. Using these exponents and monkey PK data (at >1 mg/kg) alone, both human CL and Vss of mAbs can be predicted with reasonable accuracy, i.e., within 2-fold of the observed values. Compared with traditional allometric scaling using PK data from three or more preclinical species, this approach is simple, quick, resource-saving, and useful in drug discovery and development.

1 January 2012 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
MOMasataka Oitate
Masataka Oitate
SNShintaro Nakayama
Shintaro Nakayama
TITakashi Ito
Takashi Ito
AKAtsushi Kurihara
Atsushi Kurihara
NONoriko Okudaira
Noriko Okudaira
TITakashi Izumi
Takashi Izumi
We have previously reported that human total body clearance (CL) and steady-state volume of distribution (Vss) of monoclonal antibodies (mAbs) could be predicted reasonably well from monkey data alone using simple allometry with scaling exponents of 0.79 and 1.12 (for soluble targets), and 0.96 and 1.00 (for membrane-bound targets). In the present study, to predict the plasma concentration-time profiles of mAbs in humans, we employed simple dose-normalization and species-invariant time methods (elementary Dedrick plot and complex Dedrick plot), based on the monkey data and the scaling exponents we previously determined. The results demonstrated that the species-invariant time methods were able to provide higher accuracy of prediction than simple dose-normalization, regardless of the type of target antigens (soluble or membrane-bound). The accuracy between elementary Dedrick plot and complex Dedrick plot was nearly equivalent. The predicted human CL and Vss using species-invariant time methods were within mostly 2-fold differences from the observed values. The prediction not only of pharmacokinetic (PK) parameters but also of the plasma concentration-time profile in humans can serve as guidelines for better planning of clinical studies on mAbs.

1 October 2007 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
MOMasataka Oitate
Masataka Oitate
THTakashi Hirota
Takashi Hirota
TMTakahiro Murai
Takahiro Murai
SMShin-Ichi Miura
Shin-Ichi Miura
TIToshihiko Ikeda
Toshihiko Ikeda
In rats, it has been reported that rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, reacts with the aldehyde group of allysine in elastin to give a condensation covalent adduct, thereby preventing the formation of cross-linkages in the elastin and causing degradation of the elastic fibers in aortas in vivo. Acid, organic solvent, and proteolytic enzyme treatments of human aortic homogenate after incubation with [14C]rofecoxib demonstrated that most of the radioactivity is covalently bound to elastin. The in vitro covalent binding was inhibited in the presence of β-aminopropionitrile, d-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding. The in vitro covalent binding of [14C]rofecoxib was significantly decreased by the addition of only nonradiolabeled rofecoxib but not the other COX-2 inhibitors, celecoxib, valdecoxib, etoricoxib, and CS-706 [2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole], a novel selective COX-2 inhibitor. All the above COX-2 inhibitors except for rofecoxib had no reactivity with the aldehyde group of benzaldehyde used as a model compound of allysine aldehyde under a physiological pH condition. On the other hand, no retention of the radioactivity of [14C]rofecoxib was observed in human aortic endothelial cells in vitro, suggesting that rofecoxib is not retained in aortic endothelial cells in vivo. These results suggest that rofecoxib, but not other COX-2 inhibitors, is capable of covalently binding to the aldehyde group of allysine in human elastin. This might be one of the main causes of cardiovascular events by rofecoxib in clinical situations.

1 December 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KIKentaro Ito
Kentaro Ito
GTGo Tajima
Go Tajima
CKChikako Kamisato
Chikako Kamisato
MTMiyuki Tsumura
Miyuki Tsumura
MIMitsuhiro Iwamoto
Mitsuhiro Iwamoto
KTKiyosumi Takaishi
Kiyosumi Takaishi
Glycogen storage disease type 1a (GSD1a) is caused by a congenital deficiency of glucose-6-phosphatase-α (G6Pase-α, encoded by G6PC), which is primarily associated with life-threatening hypoglycemia. Although strict dietary management substantially improves life expectancy, patients still experience intermittent hypoglycemia and develop hepatic complications. Emerging therapies utilizing new modalities such as adeno-associated virus and mRNA with lipid nanoparticles are under development for GSD1a but potentially require complicated glycemic management throughout life. Here, we present an oligonucleotide-based therapy to produce intact G6Pase-α from a pathogenic human variant, G6PC c.648G>T, the most prevalent variant in East Asia causing aberrant splicing of G6PC. DS-4108b, a splice-switching oligonucleotide, was designed to correct this aberrant splicing, especially in liver. We generated a mouse strain with homozygous knockin of this variant that well reflected the pathophysiology of patients with GSD1a. DS-4108b recovered hepatic G6Pase activity through splicing correction and prevented hypoglycemia and various hepatic abnormalities in the mice. Moreover, DS-4108b had long-lasting efficacy of more than 12 weeks in mice that received a single dose and had favorable pharmacokinetics and tolerability in mice and monkeys. These findings together indicate that this oligonucleotide-based therapy could provide a sustainable and curative therapeutic option under easy disease management for GSD1a patients with G6PC c.648G>T.

3 August 2023 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
HHHiromi Habara
Hiromi Habara
HOHiromi Okamoto
Hiromi Okamoto
YNYoko Nagai
Yoko Nagai
MOMasataka Oitate
Masataka Oitate
HTHideo Takakusa
Hideo Takakusa
NWNobuaki Watanabe
Nobuaki Watanabe

22 January 2024 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
YNYoko Nagai
Yoko Nagai
MOMasataka Oitate
Masataka Oitate
TSTakahiro Shibayama
Takahiro Shibayama
HTHideo Takakusa
Hideo Takakusa
NWNobuaki Watanabe
Nobuaki Watanabe